Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03730077 · ClinicalTrials.gov registry record · Phase 1
FMISO PET/CT Imaging Trial for Assessing Hypoxia in Soft Tissue Sarcomas
A Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03730077: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT03730077 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03730077, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
Subjects with known or suspected primary soft tissue sarcoma of the extremities may be eligible for this study. Subjects may participate in this study if they are at least 18 years of age. Most participants will be receiving care at the clinical practices of the University of Pennsylvania Health System. Positron emission tomography (PET/CT) imaging will be used to evaluate soft tissue sarcoma hypoxia using an investigational radiotracer, 18F-FMISO Subjects will also undergo an 18F-FDG PET/CT scan close to the time of their initial hypoxia PET/CT to compare in vivo measures of hypoxia to 18F-FDG uptake. The FDG PET/CT may be performed as part of standard clinical care or as a research scan. Both PET/CT scans will occur prior to starting new therapy.
Interventions
- DRUG 18F-FMISO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2021-02-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03730077
The ClinicalTrials.gov registry entry for NCT03730077 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 18F-FMISO is the first listed.
NCT03730077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03730077 about?
NCT03730077 is a clinical study titled "FMISO PET/CT Imaging Trial for Assessing Hypoxia in Soft Tissue Sarcomas". Subjects with known or suspected primary soft tissue sarcoma of the extremities may be eligible for this study. Subjects may participate in this study if they are at least 18 years of age. Most participants will be receiving care at the clinical practices of the University of Pennsylvania Health Sys...
What is the current status of trial NCT03730077?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2019-02-01. Estimated completion is 2021-02-18.
What interventions are being tested in trial NCT03730077?
The interventions under investigation include: 18F-FMISO (DRUG).
Who is sponsoring clinical trial NCT03730077?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.